cefditoren pivoxil
Drug400 mg, oral, single dose during 3 days
Other names: Meiact, Spectracef, Telo
NCT Number: NCT00598403
The main objective of the study is to comparatively assess the efficacy and tolerability of the drugs under study in the treatment of acute uncomplicated cystitis.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 3
General Hospital of Chest Disease of Athens, Athens, Greece
Urinary tract infections (UTI) are one of the most frequent reasons of surgery visits in Primary Care. More than 95 percent of UTIs are monomicrobial, although the microorganisms implied are varied, and the range of effective drugs could be extensive. The species most frequently isolated is Escherichia coli, with prevalence ranking between 85 and 90 percent of documented cases. E. coli has developed resistance to different antibiotics. Cefditoren is situated as a good candidate for the treatment of uncomplicated UTIs due to its spectrum of activity against E. coli. The study has been designed in accordance with the guidelines and recommendations in force to assess the efficacy of cefditoren pivoxil against ciprofloxacin, a drug which despite the increasing rate of resistance in some countries, continues to be a drug of choice for the treatment of uncomplicated UTIs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
400 mg, oral, single dose during 3 days
Other names: Meiact, Spectracef, Telo
250 mg, oral, twice a day for 3 days
Other names: Ciprofloxacino Mabo
Time frame: 5-9 days post-therapy
Time frame: 5-9 days post-therapy
Tedec-Meiji Farma, S.A.
Industry
Multicentre, Prospective, Comparative, Randomized, Double-blind, Double-dummy Study to Assess the Efficacy and Safety of Cefditoren Pivoxil vs. Ciprofloxacin in Uncomplicated Acute Cystitis
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05584657
Cystitis, Female Urogenital Diseases
Cullman, Alabama, United States
View Trial DetailsNCT04987164
Cystitis, Female Urogenital Diseases
Dijon, Bourgogne-Franche-Comté, France
View Trial DetailsNCT02832258
Cystitis, Female Urogenital Diseases
Boulogne-Billancourt, France
View Trial DetailsNCT00210886
Cystitis, Female Urogenital Diseases
View Trial Details